Inside Nephrology: A Weekly Review
Nefrologia
From Cells to Signals: The Future of Autoimmunity in Nephrology
In this episode of Inside Nephrology: A Weekly Review, we dive into cutting-edge advances in cellular therapy and precision medicine transforming autoimmune disease treatment. Highlights include promising CAR-T cell therapy in juvenile autoimmune conditions, the expanding role of SGLT2 inhibitors, gene-environment insights into serum urate regulation, microRNA impacts on secondary hyperparathyroidism, novel transplant rejection therapies, and encouraging results of avacopan in elderly patients with ANCA-associated vasculitis. Stay informed on these groundbreaking developments shaping the future of nephrology and patient care.
Bibliography
References:
– Soliman AR et al. The evolution of nephrology practice in Egypt: legacy, current challenges, and future directions: a narrative review. Ren Fail. 2025;47(1):2509784.
– Jouret M et al. CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? Arthritis Res Ther. 2025;27(1):102.
– Kronbichler A. Sodium-glucose cotransporter 2 (SGLT2) inhibition and autoimmunity. Semin Arthritis Rheum. 2025;72S:152663.
– Fujii W et al. Gene-environment interaction modifies association between hyperinsulinemia and serum urate levels through SLC22A12. J Clin Invest. 2025;135(10):e186633.
– Lu Z et al. miRNAs in secondary hyperparathyroidism: literature review. BMC Nephrol. 2025;26(1):250.
– Lyu G et al. Ferroptosis and renal fibrosis: mechanistic insights and emerging therapeutic targets. Ren Fail. 2025;47(1):2498629.
– Mayer KA et al. Targeting CD38 in antibody-mediated rejection. Transpl Int. 2025;38:14343.
– Geetha D et al. Efficacy and safety of avacopan in patients aged 65+ with ANCA-associated vasculitis: post hoc analysis of ADVOCATE trial data. Rheumatology (Oxford). 2025;64(6):3863-3871.
– Gen S et al. Edoxaban-induced acute interstitial nephritis. CEN Case Rep. 2025;14(3):301-305.
– Schork A et al. Differential risk assessment in persons at risk of type 2 diabetes using urinary peptidomics. Metabolism. 2025;167:156174.